APEC Leaders’ Endorsement of the Nanjing Declaration Welcomed by Rx&D and MEDEC

Ottawa, November 17 – Canada’s Research-Based Pharmaceutical Companies (Rx&D) and MEDEC – Canada’s Medical Technology Companies – welcome the Asia-Pacific Economic Cooperation (APEC) Leaders’ (Heads of State) endorsement of the Nanjing Declaration to Promote Ethical Business Environments in the Medical Device and Biopharmaceutical Sectors (2014-2020).

“We welcome the APEC leader’s endorsement of strong and principled ethical business environments in the APEC region. This endorsement further solidifies the success that APEC’s Biopharmaceutical Industry Ethics Team has had in engaging stakeholders from different sectors the world over,” said Russell Williams, President of Rx&D. “As the industry organization representing the innovative pharmaceutical sector in Canada, there is an expectation for our industry to meet the highest standards of business practice regardless of where we operate. We are pleased to see that the initiative’s biopharmaceutical and device sector programs continue to demonstrate notable success in facilitating the implementation of codes of ethics by industry associations in alignment with APEC’s Mexico City Principles.”

This year’s declaration marks the second occasion that APEC leaders have expressed support for the APEC Biopharmaceutical Industry Ethics Team, as endorsed through the 2014 APEC Leaders’ Declaration that was released on November 8 in Beijing, following the 26th APEC Ministerial Meeting.

“It is of important significance to the Canadian medical technology sector that APEC Ministers have endorsed the work of the Nanjing Declaration, especially given the work MEDEC has done with APEC to produce a common set of ethical principles that will be adopted globally,” said Brian Lewis, President and CEO of MEDEC. “We applaud APEC leaders for their recognition of this important work and we look forward to continuing to work with the APEC Medical Device Working Group on Ethics to advance these ethical principles in the medical technology sector around the world.”

About Rx&D

Canada’s Research-Based Pharmaceutical Companies is the national association representing the voice of Canada’s innovative pharmaceutical industry. We serve our membership by advocating for policies that enable the discovery, development and delivery of innovative medicines and vaccines to improve the lives of all Canadians. We support our memberships’ commitment to being a valued partner in the Canadian healthcare system. We represent more than 50 companies investing over $1-billion in R&D annually, fuelling Canada’s knowledge-based economy, while contributing over $3-billion overall to
Canada’s economy. Guided by our Code of Ethical Practices, we work with governments, private payers, healthcare professionals and stakeholders in a highly ethical manner.

About MEDEC

MEDEC is the national association representing the medical technology industry in Canada. Our members are committed to providing safe and innovative medical technologies that enhance the quality of patient care, improve patient access to health care, and help enable the sustainability of our publicly-funded health care system. The medical technology industry in Canada employs over 35,000 Canadians in approximately 1,500 facilities, and has sales of over $7 billion per annum. We are committed to supporting the growth of a strong and vibrant medical technology industry that contributes to Canada’s innovation economy.

– 30 –

For further information:

Sarah Douglas
Media Relations, Rx&D
Telephone: 613-236-04-55 ext. 525
Email: sdouglas@canadapharma.org

Gerry Frenette
Executive Director, Public and Member Relations, MEDEC
Telephone: 416-641-2744
Email: gfrenette@medec.org